An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Inclusion Criteria Patients must have: Patients > 18 months of age with history of positive serology for HIV-1 infection or patients <= 18 months of age with history of positive viral culture, detectable p24 antigen, or positive peripheral blood mononuclear cell macro culture. Patients >= 13 years of age with a CD4+ cell count <= 200 cells/mm3. Patients < 13 years of age with a CD4% <= 14% or a 50% decrease in CD4% in the past 6 months if the previous CD4% was >=20%. Patient has failed or is intolerant to currently approved treatments for HIV-1 infection and is unable to participate in a controlled viramune clinical trial. Written and informed consent from a parent or guardian for patients < 18 years of age. Patient or guardian is willing and able to follow protocol requirements. (PER AMENDMENT 1/29/97: Enrollment is closed to adults, as of Jan. 29th only pediatric patients will be enrolled.) Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Patient qualifies for participation in an actively accruing Viramune controlled clinical trial. Concurrent Medication: Excluded: Dicumarol, Warfarin, and other anticoagulant medications. Tolbutamide. Investigational drugs, all protease inhibitors, and all other non-nucleoside transcriptase inhibitors. Neurotoxic drugs. Cimetidine. Erythromycin. Required: Patient has failed or is intolerant to currently approved treatments for HIV-1 infection.